Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia

JW Pharmaceutical6,927 enrolled

Overview

A Multi-center, Open-label, Observational Study to evaluate the Efficacy and Safety of Pitavastatin/Ezetimibe after switching from Statin Monotherapy to Pitavastatin/Ezetimibe in patients with Hypercholesterolemia

A Multi-center, Open-label, Observational Study

Study Type

OBSERVATIONAL

Enrollment

6,927

Conditions

Hypercholesterolemia

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults (≥19 years) with hypercholesterolemia. * On a stable dose of statin monotherapy for at least 8 weeks. * Scheduled to switch to Pitavastatin/Ezetimibe per investigator's decision. * Provided voluntary written informed consent. Exclusion Criteria: * Use of other lipid-lowering therapies within 4 weeks before screening. * History of clinically significant laboratory abnormalities within 1 year. * Participation in other clinical trials within 4 weeks. * Contraindications to Pitavastatin/Ezetimibe

Locations (1)

Seoul Metropolitan Government Seoul National University Boramae Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

LDL-C level

Percent change from baseline in LDL-C level at Week 24

Time frame: From enrollment to the end of treatment at 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.